Earnings Insights · CORZ · Q3 FY2026
Core Scientific Q3 2026 Earnings: Colocation Ramp Drives Revenue and EBITDA Step-Up
By AlgovestIQ ResearchPublished
Read Core Scientific’s results announcement (Form 8-K, filed Nov 5, 2026)
Key earnings findings
Core Scientific (CORZ) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Core Scientific reported Q3 FY2026 revenue of $232.9M against the $196.4M analyst estimate, a 18.6% beat, and EPS of $0.47 against the -$0.05 analyst estimate.
- Management maintained expected construction costs of approximately $11M to $12M per MW for the current AMD leases.
- CORZ closed at $11.38 on Nov 5, 2026, down 10.8% from $12.76 on Nov 4, 2026, the last close before the results were released.
Sources: Core Scientific results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Core Scientific beat earnings expectations?
- Revenue surprise across the last 8 reported quarters has ranged from -33.0% to 18.6%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Core Scientific reported Q3 revenue of $232.9M, up from $164.2M in Q2, as high-density colocation revenue rose nearly 60% sequentially to $215.4M. GAAP net income was $1.18B, or $3.42 per basic share and $0.47 per diluted share, but the result was principally driven by a $1.03B non-cash gain from the change in fair value of warrants and contingent value rights.
The more relevant operating result was the rapid expansion of the colocation business. Billing capacity reached 485 MW at quarter-end, adjusted EBITDA increased to $133.6M from $41.1M in Q2, and consolidated gross margin rose to 53% from 43%. The investment case now rests on completing the final portion of the CoreWeave deployment, financing and delivering the first 530 MW of AMD capacity, and converting AMD’s 1.9 GW of reservation rights into firm commitments.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Total revenue | $232.9M | Up 42% sequentially; up from $81.1M a year earlier |
| Colocation revenue | $215.4M | Up 58% sequentially |
| Billing capacity | 485 MW | Up from 395 MW in Q2 |
| Gross profit | $123.3M | Up from $70.0M in Q2 |
| Consolidated gross margin | 53% | Up from 43% in Q2 |
| Colocation gross margin | 60% | Up from 59% in Q2 |
| Operating income (loss) | $72.4M | Improved from a $78.5M loss in Q2 |
| Net income (loss) | $1.18B | Improved from a $1.16B loss in Q2 |
| Diluted EPS | $0.47 | Improved from a $3.32 loss in Q2 |
| Adjusted EBITDA | $133.6M | Up from $41.1M in Q2 |
| Capital expenditures | $985.1M | Up from $797.5M in Q2 |
| Liquidity and debt service reserve accounts | $1.74B | Down from $2.60B in Q2 |
The Bigger Story
Core Scientific is moving from a mixed digital-asset mining and hosting model to a colocation-focused data-center operator. The Q3 results show that the transition is beginning to produce the intended financial effect: recurring colocation revenue is replacing a shrinking mining business, and the higher-margin colocation mix is lifting consolidated profitability.
The company brought another 90 MW into billing during the quarter and ended September with 485 MW of billable capacity under its initial 590 MW CoreWeave agreement. Management expects the remaining roughly 100 MW, primarily tied to Dalton Phase 2, to enter service by early 2027.
That final CoreWeave ramp is important because it will provide a more complete view of the earnings power of the existing colocation portfolio before the AMD program begins contributing meaningfully. Management expects the combined 1.1 GW currently contracted with CoreWeave and AMD to generate $1.8B of average annual run-rate revenue and $1.6B of NOI once fully delivered and billing. Those are management projections rather than current results, and much of the AMD capacity will not enter service until 2027 and 2028.
Revenue and Operating Performance
Colocation accounted for 92% of Q3 revenue, compared with 83% in Q2 and only 18% a year earlier. Colocation revenue reached $215.4M, including $157.3M in license fees and $57.6M of power fees passed through to the customer.
The revenue increase reflected both the 90 MW brought into billing during Q3 and a full-quarter contribution from capacity delivered during the second quarter. Management said it was billing for 485 MW at September 30, representing more than $700M of average annualized colocation GAAP revenue.
The underlying quality of revenue improved alongside the mix shift. Core Scientific’s colocation arrangements with CoreWeave are recognized on a straight-line GAAP basis over 12-year lease terms, which management said effectively pulls forward contractual price escalators. That accounting treatment supports near-term reported revenue but also means quarterly revenue does not simply track the timing of cash payments or capacity additions.
Digital-asset self-mining continued to decline as the company winds down its remaining mining operations. Self-mining revenue fell to $12.3M from $21.5M in Q2 and $57.4M a year ago. The business produced a gross loss of $7.5M, equivalent to a negative 61% gross margin. Management expects to complete the mining exit in Q4 and enter 2027 as a pure-play high-density colocation provider.
Hosted mining revenue was $5.2M, down modestly from $6.0M in Q2. While hosted mining remained profitable at the gross-profit level, it has become immaterial to the company’s strategic direction.
Profitability and Margins
Gross profit increased to $123.3M from $70.0M in Q2, lifting consolidated gross margin by 10 percentage points to 53%. The expansion was driven by colocation scale rather than lower costs in the legacy mining operations.
Colocation gross profit rose to $128.4M from $80.0M in the prior quarter, while colocation gross margin reached 60%. Power fees passed through to customers represented $57.6M of both revenue and cost of colocation services, so the higher-margin license-fee component is more indicative of the segment’s underlying profitability.
Operating income was $72.4M, compared with an operating loss of $78.5M in Q2. The improvement reflected the larger gross-profit base and lower colocation organizational and startup costs, which fell to $12.9M from $27.0M in Q2. SG&A declined modestly to $45.6M from $49.0M, although stock-based compensation remained substantial at $25.2M.
Adjusted EBITDA more than tripled sequentially to $133.6M, producing a 57% adjusted EBITDA margin versus 25% in Q2. The measure excludes, among other items, warrant revaluations, stock-based compensation, depreciation, startup costs, merger-related advisory fees, and other non-recurring or non-cash items.
GAAP net income should be read cautiously. The $1.18B profit was driven primarily by a $1.03B non-cash gain on the remeasurement of warrant and contingent value-right liabilities. The same accounting item generated a $1.05B expense in Q2, explaining the large swing from a quarterly net loss to net income. Diluted EPS of $0.47 also reflects the larger diluted share count associated with warrants.
Demand, Customers and Pricing
Core Scientific’s near-term contracted growth remains concentrated in its two disclosed colocation customers, CoreWeave and AMD. The company has approximately 1.1 GW of contracted capacity between them: 590 MW with CoreWeave and an initial 530 MW with AMD.
Management said the 530 MW AMD commitment represents more than half of the company’s contracted stabilized NOI, despite accounting for less than half of contracted capacity. Initial AMD deliveries are expected to begin at Pecos in the first half of 2027, with approximately half of the 530 MW expected online next year and the balance delivered through 2028.
AMD also holds exclusive reservation rights for approximately 1.9 GW across Muskogee, Hunt, and Pecos. Most commitment deadlines fall in 2027, with the final deadline at the end of 2028. These reservations create a significant potential development pipeline, but they are not yet contracted revenue or committed capacity.
Management expects pricing for any incremental AMD commitments to reflect the agreed design, prevailing market rates, and development costs, with the objective of maintaining substantially similar returns. That framing matters as data-center construction and financing costs remain elevated. Management also said customers are increasingly evaluating tradeoffs between cost and reliability specifications, suggesting future project economics will depend partly on the required design standard and workload needs.
What is Core Scientific’s outlook for Q4 2026 and beyond?
Core Scientific did not provide formal Q4 revenue, EBITDA, EPS, or margin guidance. Management said it expects a double-digit sequential increase in Q4 revenue as additional capacity enters billing and previously delivered capacity contributes for a full quarter.
The remaining CoreWeave capacity is expected to come online over the next several months, with the final approximately 100 MW targeted for delivery by early 2027. Management expects to complete the shutdown of Bitcoin mining operations during Q4.
For the AMD program, management expects initial delivery at Pecos in the first half of 2027. About half of the initial 530 MW is expected online during 2027, with the remainder delivered through 2028. Management maintained expected construction costs of approximately $11M to $12M per MW for the current AMD leases.
Core Scientific is also assessing approximately 2 GW of potential capacity at new sites, with energization expected in 2029 and beyond. Management said it intends to remain selective on acquisitions and new development, prioritizing the delivery of its existing contracts.
Balance Sheet, Cash Flow and Capital
The company ended Q3 with $803.9M of cash and cash equivalents, $837.6M of restricted cash, and $100M of revolver availability. Its reported liquidity and debt service reserve measure was $1.74B, down from $2.60B at the end of Q2.
The decline reflected substantial investment in the AMD build-out and the Polaris acquisition. Management said liquidity fell by about $1B during the quarter, including approximately $540M of CapEx primarily related to AMD sites and roughly $440M tied to the Polaris transaction. Reported quarterly CapEx, which includes property, plant and equipment purchases and acquisitions of land and development rights, was $985.1M.
Long-term debt was $4.30B at quarter-end, essentially unchanged from Q2 but sharply higher than $1.06B at year-end 2025. Over the first nine months of 2026, the company issued $4.28B of debt and used $1.0B for debt extinguishment payments. Interest expense was $35.0M in Q3, up from $23.8M in Q2.
Management said Core Scientific has already invested all equity capital required for the initial 530 MW AMD build-out. The remaining funding need is expected to be addressed through project bonds or other debt financing. Management does not expect to issue additional equity or equity-linked securities to fund this initial AMD phase.
The company also expects approximately $650M in cash proceeds from Tranche 1 warrant exercises around their January 2027 expiration. Management said the expected proceeds would primarily support future proactive development, including capacity that could be committed under AMD’s reservation rights.
What Investors Should Watch
1. Completion of the CoreWeave Ramp
The final CoreWeave capacity is the most immediate operating milestone. Bringing the remaining roughly 100 MW into billing would support another step-up in colocation revenue and provide a clearer baseline for the standalone colocation model after the mining exit.
2. AMD Project Financing
Core Scientific still needs to secure project financing for the AMD development program. Management said the project-bond market remains open and that financing discussions are progressing, but execution on funding structure, cost of capital, and timing will be critical ahead of 2027 deliveries.
3. AMD Reservation Conversions
The 1.9 GW of AMD reservation rights represents significant optionality but is not yet committed capacity. Investors should monitor whether AMD exercises its 2027 commitment deadlines and whether the resulting projects preserve the returns management expects.
4. Regulatory and Permitting Execution
Management expressed confidence that current Texas projects remain on schedule, citing progress on permits, ERCOT review, and construction. Still, Pecos and Hunt require continued execution through remaining regulatory processes, and future behind-the-meter generation plans would require additional permitting and partner selection.
5. Leverage and Capital Intensity
The colocation ramp is producing higher EBITDA, but it is also capital intensive. Investors should watch debt growth, interest expense, restricted cash requirements, project-financing terms, and whether warrant proceeds reduce the need for additional external capital.
AlgovestIQ Takeaway
Core Scientific’s Q3 operating results were materially stronger than the GAAP headline alone suggests. The important development was not the $1.18B net income, which largely reflected warrant accounting, but the rise in colocation revenue to $215.4M, the increase in billing capacity to 485 MW, and adjusted EBITDA growth to $133.6M.
The company is demonstrating that its CoreWeave build-out can translate into meaningful revenue and margin expansion. Colocation gross margin reached 60%, while the declining mining business is being removed from the portfolio. A clean exit from mining in Q4 should make the 2027 income statement easier to evaluate as a colocation business.
The unresolved issue is capital deployment. Core Scientific has already committed equity to the first AMD phase, but it must still secure project financing while carrying $4.30B of long-term debt and funding a large construction program. Management’s expected $650M of warrant-exercise proceeds would improve flexibility, but it does not eliminate execution risk around the AMD rollout.
The central investment question has shifted from whether Core Scientific can bring its first large-scale colocation contract online to whether it can repeat that execution with AMD while preserving project returns and balance-sheet flexibility. Evidence that the thesis is strengthening would include final CoreWeave delivery, double-digit Q4 revenue growth, project-financing completion, and early AMD construction milestones. Delays in permitting, financing, or customer commitments would carry greater weight as the company moves into its next, more capital-intensive phase.
How did CORZ stock react?
CORZ closed at $11.38 on Nov 5, 2026, down 10.8% from $12.76 on Nov 4, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Nov 4, 2026 (before release) | $12.76 | — |
| Nov 5, 2026 | $11.38 | -10.8% |
| Nov 6, 2026 | $11.76 | -7.8% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- NETCloudflare Q3 2026 Earnings: Growth Accelerates as Workers and Enterprise Demand StrengthenNov 5, 2026
- XYZBlock Q3 2026 Earnings: Margin Expansion Accelerates as Cash App and Square Growth StrengthenNov 3, 2026
- TOSTToast Q3 2026 Earnings: Profitability Scales as Location Growth and Monetization Remain StrongNov 3, 2026
- PLTRPalantir Q3 2026 Earnings: U.S. Commercial Revenue Overtakes Government as Growth AcceleratesNov 2, 2026
- TWLOTwilio Q3 2026 Earnings: Organic Growth Holds at 16% as Profit and Cash Flow Reach RecordsOct 29, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Core Scientific Q3 FY2026 earnings call transcript, as of Nov 5, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Core Scientific Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 5, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 5, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.